rolipram has been researched along with Pneumonia in 12 studies
Pneumonia: Infection of the lung often accompanied by inflammation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Roflumilast did not inhibit serotonin-induced bronchoconstriction 4." | 5.33 | Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors. ( Beume, R; Bundschuh, DS; Marx, D; Wohlsen, A; Wollin, L, 2006) |
| "Theophylline is a difficult drug to use clinically, requiring careful titration and routine plasma monitoring due to the risk of toxic side effects, such as cardiovascular and central nervous system adverse events, with dose adjustments required in many patients, including smokers, the elderly and some patients on concomitant medications." | 2.42 | PDE4 inhibitors in COPD--a more selective approach to treatment. ( Vignola, AM, 2004) |
| "Pneumococcal pneumonia is a leading cause of mortality worldwide." | 1.43 | Inhibition of Phosphodiesterase-4 during Pneumococcal Pneumonia Reduces Inflammation and Lung Injury in Mice. ( David, BA; Galvão, I; Garcia, CC; Queiroz-Junior, CM; Rachid, MA; Russo, RC; Silva, PM; Sousa, LP; Tavares, LP; Teixeira, MM; Vago, JP, 2016) |
| "Acute pulmonary inflammation is characterized by migration of polymorphonuclear neutrophils (PMNs) into the different compartments of the lung, passing an endothelial and epithelial barrier." | 1.42 | The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation. ( Bury, A; Konrad, FM; Ngamsri, KC; Reutershan, J; Schick, MA, 2015) |
| "Airway hyperreactivity (AHR), lung inflammation, and atopy are clinical signs of allergic asthma." | 1.35 | Maternal exposure to secondhand cigarette smoke primes the lung for induction of phosphodiesterase-4D5 isozyme and exacerbated Th2 responses: rolipram attenuates the airway hyperreactivity and muscarinic receptor expression but not lung inflammation and a ( Campen, M; Kurup, V; Mishra, NC; Razani-Boroujerdi, S; Rir-Sima-Ah, J; Singh, SP; Sopori, ML, 2009) |
| "Roflumilast did not inhibit serotonin-induced bronchoconstriction 4." | 1.33 | Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors. ( Beume, R; Bundschuh, DS; Marx, D; Wohlsen, A; Wollin, L, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kümmerle, AE | 1 |
| Schmitt, M | 1 |
| Cardozo, SV | 1 |
| Lugnier, C | 2 |
| Villa, P | 1 |
| Lopes, AB | 1 |
| Romeiro, NC | 1 |
| Justiniano, H | 1 |
| Martins, MA | 1 |
| Fraga, CA | 1 |
| Bourguignon, JJ | 1 |
| Barreiro, EJ | 1 |
| Konrad, FM | 1 |
| Bury, A | 1 |
| Schick, MA | 1 |
| Ngamsri, KC | 1 |
| Reutershan, J | 1 |
| Tavares, LP | 1 |
| Garcia, CC | 1 |
| Vago, JP | 1 |
| Queiroz-Junior, CM | 1 |
| Galvão, I | 1 |
| David, BA | 1 |
| Rachid, MA | 1 |
| Silva, PM | 1 |
| Russo, RC | 1 |
| Teixeira, MM | 1 |
| Sousa, LP | 1 |
| Sharma, R | 1 |
| Kaundal, RK | 1 |
| Sharma, SS | 1 |
| Singh, SP | 1 |
| Mishra, NC | 1 |
| Rir-Sima-Ah, J | 1 |
| Campen, M | 1 |
| Kurup, V | 1 |
| Razani-Boroujerdi, S | 1 |
| Sopori, ML | 1 |
| Smith, KR | 1 |
| Leonard, D | 1 |
| McDonald, JD | 1 |
| Tesfaigzi, Y | 1 |
| Yougbare, I | 1 |
| Morin, C | 1 |
| Senouvo, FY | 1 |
| Sirois, C | 1 |
| Albadine, R | 1 |
| Rousseau, E | 1 |
| Vignola, AM | 1 |
| Wollin, L | 1 |
| Bundschuh, DS | 1 |
| Wohlsen, A | 1 |
| Marx, D | 1 |
| Beume, R | 1 |
| Gonçalves de Moraes, VL | 1 |
| Singer, M | 1 |
| Vargaftig, BB | 1 |
| Chignard, M | 1 |
| Manabe, H | 1 |
| Akuta, K | 1 |
| Kawasaki, H | 1 |
| Ohmori, K | 1 |
| Toward, TJ | 1 |
| Broadley, KJ | 1 |
1 review available for rolipram and Pneumonia
| Article | Year |
|---|---|
PDE4 inhibitors in COPD--a more selective approach to treatment.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Benzamides; Bronchodilator Agents; Carboxylic A | 2004 |
11 other studies available for rolipram and Pneumonia
| Article | Year |
|---|---|
Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.
Topics: Administration, Oral; Animals; Drug Design; Female; Humans; Hydrazones; Magnetic Resonance Spectrosc | 2012 |
The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation.
Topics: Aminopyridines; Animals; Benzamides; Capillary Permeability; Chemokines; Cyclic Nucleotide Phosphodi | 2015 |
Inhibition of Phosphodiesterase-4 during Pneumococcal Pneumonia Reduces Inflammation and Lung Injury in Mice.
Topics: Animals; Annexin A1; Anti-Bacterial Agents; Ceftriaxone; Cyclic Nucleotide Phosphodiesterases, Type | 2016 |
Amelioration of pulmonary dysfunction and neutrophilic inflammation by PPAR gamma agonist in LPS-exposed guinea pigs.
Topics: Administration, Inhalation; Animals; Bronchoalveolar Lavage Fluid; Escherichia coli Proteins; Guinea | 2009 |
Maternal exposure to secondhand cigarette smoke primes the lung for induction of phosphodiesterase-4D5 isozyme and exacerbated Th2 responses: rolipram attenuates the airway hyperreactivity and muscarinic receptor expression but not lung inflammation and a
Topics: Airway Resistance; Allergens; Animals; Bronchial Hyperreactivity; Cyclic Nucleotide Phosphodiesteras | 2009 |
Inflammation, mucous cell metaplasia, and Bcl-2 expression in response to inhaled lipopolysaccharide aerosol and effect of rolipram.
Topics: Aerosols; Animals; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; Chemokines; Cytokines; Do | 2011 |
NCS 613, a potent and specific PDE4 inhibitor, displays anti-inflammatory effects on human lung tissues.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Anti-Inflammatory Agents; Asthma | 2011 |
Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Aminopyridines; Animals; Benzamides; Bron | 2006 |
Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung.
Topics: Animals; Cyclic AMP; Gene Expression Regulation; Lipopolysaccharides; Macrophages, Alveolar; Male; M | 1998 |
The inhaled administration of KF19514, a phosphodiesterase 4 and 1 inhibitor, prevents antigen-induced lung inflammation in guinea pigs.
Topics: Acetylcholine; Administration, Inhalation; Airway Resistance; Aminophylline; Animals; Asthma; Bronch | 2000 |
Chronic lipopolysaccharide exposure on airway function, cell infiltration, and nitric oxide generation in conscious guinea pigs: effect of rolipram and dexamethasone.
Topics: Animals; Anti-Inflammatory Agents; Bronchoconstriction; Cell Movement; Dexamethasone; Eosinophils; G | 2001 |